SCHEMBL995392

SCHEMBL995392

C=C(CCC(NC)(NC)NC)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 5/20 0.38
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TET3 O43151 1/20 0.31
TET1 Q8NFU7 1/20 0.31
GRIK1 P39086 1/20 0.30
GRIK2 Q13002 1/20 0.30
GRM1 Q13255 1/20 0.30
GRM2 Q14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL161220 0.98 TET2 (0.36) TET2ALOX15HSD17B10TET3TET1
Bromide SCHEMBL8931105 0.98 TET2 (0.36) TET2ALOX15HSD17B10TET3TET1
Sulfuric Acid SCHEMBL9103493 0.92 TET2 (0.33) TET2ALOX15HSD17B10
SCHEMBL4654955 0.88 TET2 (0.35) TET2ALOX15HSD17B10
SCHEMBL1770041 0.86 TET2 (0.30) TET2
Hydrochloric Acid SCHEMBL4387248 0.86 TET2 (0.34) TET2ALOX15HSD17B10
SCHEMBL7856854 0.85 LMNA (0.40) ALOX15
SCHEMBL1006556 0.79 TET2 (0.35) TET2ALOX15HSD17B10
Hydrochloric Acid SCHEMBL7764314 0.78 TET2 (0.34) TET2ALOX15HSD17B10
SCHEMBL1018910 0.77 TET2 (0.50) TET2ALOX15HSD17B10TET3TET1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3788125-B1 DISHWASHING DETERGENT FORMULATIONS COMPRISING POLYASPARTIC ACID AND GRAFT POLYMERS BASED ON OLIGO- AND POLYSACCHARIDES AS FILM INHIBITING ADDITIVES BASF SE (DE) 2024-03-13 EP claimed
EP-4294559-A1 POROUS SORPTIVE SOLID PHASE MICROEXTRACTION DEVICES AND PREPARATION THEREOF Memorial University of Newfoundland (CA) 2023-12-27 EP claimed
WO-2018137686-A9 DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES Triastek, Inc. (CN) 2018-12-27 WO claimed
WO-2018137686-A1 DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES Triastek, Inc. (CN) 2018-08-02 WO claimed
EP-2086519-B1 CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS HANALL BIOPHARMA CO LTD (KR) 2017-06-21 EP claimed
US-9303096-B2 Expandable elastomeric material in the presence of water or oil RHODIA OPERATIONS (FR) 2016-04-05 US claimed
US-8642083-B2 Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors HANALL BIOPHARMA CO., LTD. (KR) 2014-02-04 US claimed
EP-2373774-B1 IMPROVEMENTS RELATING TO FABRIC CONDITIONERS UNILEVER PLC (GB) 2013-03-20 EP claimed
EP-1173878-B1 PROBES FOR A GAS PHASE ION SPECTROMETER BIO RAD LABORATORIES (US) 2011-04-06 EP claimed
EP-1909741-B1 denture support composition RECKITT BENCKISER UK LTD (GB) 2010-11-10 EP claimed
WO-2007145991-A2 ANTI-INFLAMMATORY AND ANALGESIC COMPOSITIONS AND RELATED METHODS LIPOCINE, INC. (US) 2007-12-21 WO claimed
US-20070281927-A1 Anti-inflammatory and analgesic compositions and related methods LIPOCINE, INC. 2007-12-06 US claimed
US-20070275061-A1 PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS OF METFORMIN EXTENDED RELEASE TABLETS HANALL PHARMACEUTICAL CO., LTD. (KR) 2007-11-29 US claimed
WO-2005123138-A9 PHARMACEUTICAL PELLET COMPOSITIONS FOR CONTROLLED RELEASE CHONG KUN DANG PHARM CORP (KR) 2006-04-06 WO claimed
WO-2005123138-A1 PHARMACEUTICAL PELLET COMPOSITIONS FOR CONTROLLED RELEASE CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2005-12-29 WO claimed
EP-0923611-B1 POLYACRYLAMIDE POLYMERISATION ICI PLC (GB) 2004-01-28 EP claimed
WO-2001006011-A2 ARRAYS COMPRISING NON-COVALENTLY ASSOCIATED NUCLEIC ACID PROBES AND METHODS FOR MAKING AND USING THEM GENOMETRIX GENOMICS, INC. (US) 2001-01-25 WO claimed
EP-0646038-B1 PASSIVATED AND STABILIZED POROUS SUPPORTS AND METHODS FOR THE PREPARATION AND USE OF SAME LIFE TECHNOLOGIES INC (US) 2000-11-15 EP claimed
EP-0580529-B1 Process for making paper or cardboard having improved retention S N F (FR) 1996-04-17 EP claimed
EP-0580529-A1 Process for making paper or cardboard having improved retention S. N. F. (FR) 1994-01-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281927-A1 Anti-inflammatory and analgesic compositions and related methods MB, PTGS1, PTGS2 TET2 2495/4885ALOX15 19/4885HSD17B10 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.